Midostaurin is a multi-kinase inhibitor that was initially targeted toward PKC and is currently approved for acute myelogenous leukemia (AML) with an Fms-like tyrosine kinase 3 (FLT3) mutation and advanced systemic mastocytosis (SM)42,43. This evidence concerns the gene PRRT2 and acute myeloid leukemia.